The failure of Novartis's antisense drug Pella Carson, contrasted with the potential success of Amgen's siRNA targeting the same pathway, could have a profound negative impact on the entire antisense field, favoring siRNA technology for large population diseases.

A promising drug can be rendered obsolete if a competitor develops a superior, disease-modifying therapy that eliminates the original market need. This highlights that competitive dynamics are as critical as scientific validity, as when a cystic fibrosis therapy was sidelined by Vertex's core treatment.

While its massive Phase 3 trial for an antisense drug was ongoing, Novartis licensed an siRNA targeting the same LP(a) pathway from a Chinese company. This proactive move suggests Novartis was either building a next-generation follow-on or, more likely, hedging its bets due to a lack of internal confidence in its lead asset's modality.

The current market prefers funding drugs for clinically validated targets, reducing 'biology risk'. However, this floods popular targets with dozens of competitors, creating immense 'commercial risk' where only one or two can truly succeed in a crowded field, a potentially worse gamble.

The upcoming Phase 3 data for Pelacarsen is the first to test the LP(a) reduction hypothesis. Since it has lower efficacy than competitors, a positive result would validate the target for the entire field, including three other Phase 3 programs, and influence preclinical development decisions.

Novartis's cardio drug failure in a secondary prevention trial highlights a critical development challenge: even for genetically-validated targets, intervening late in a chronic disease's progression may be ineffective. The damage may already be too extensive, suggesting earlier treatment is needed to show a benefit.

Novartis's Lp(a) drug may have failed not because the target is wrong, but because patients were already so well-treated with existing drugs like statins. This highlights a growing challenge: new therapies must demonstrate significant added value over an increasingly effective standard of care.

The surprising failures of Novartis's and Novo Nordisk's heart drugs, both targeting 'genetically validated' pathways, have debunked the widely held belief that genetic data guarantees clinical success. This forces a fundamental rethink of using genetics to de-risk massive drug development investments.

Even while its antisense drug Pella Carson was in a major Phase 3 trial, Novartis proactively licensed a competing siRNA technology for the same target. This suggests a sophisticated hedging strategy or internal doubts about the original drug's prospects, a move made years before the trial's failure.